Rituximab-Associated Liver Toxicity Without Known Viral Reactivation.
Publication/Presentation Date
7-1-2024
Abstract
Rituximab is a targeted immunotherapeutic agent that has demonstrated efficacy in treating CD20+ B-cell neoplasms as well as other lymphoproliferative and autoimmune disorders. A major adverse effect of rituximab is hepatocellular injury attributed to hepatitis B viral reactivation, necessitating viral titers before treatment. In this case report, we illustrate the rare presentation of a patient with marginal zone B-cell lymphoma who experienced symptomatic liver injury with a peak 15-fold aminotransferase elevation following his first dose of rituximab, without evidence of viral reactivation.
Volume
16
Issue
7
First Page
64331
Last Page
64331
ISSN
2168-8184
Published In/Presented At
Huda, T., Hussain, F., Mani, H., Gheith, S. M., & Skandan, S. (2024). Rituximab-Associated Liver Toxicity Without Known Viral Reactivation. Cureus, 16(7), e64331. https://doi.org/10.7759/cureus.64331
PubMedID
39130968
Department(s)
Department of Medicine, Hematology-Medical Oncology Division Fellows and Residents, Hematology-Medical Oncology Division, USF-LVHN SELECT Program, USF-LVHN SELECT Program Students, Department of Pathology and Laboratory Medicine
Document Type
Article